Announcements Trials
Browse Landscape

Phase

Phase 2 1

Status

Active not recruiting 1

Sponsor Class

OTHER 1

Study Type

Interventional 1

Sponsor

Cancer Type

Other hematologic neoplasm 1Lymphoid 1

Conditions

Multiple Myeloma 72Lymphoma, Follicular 23Lymphoma, Large B-Cell, Diffuse 19Lymphoma, Mantle-Cell 11Recurrence 9Lymphoma, B-Cell, Marginal Zone 9Lymphoma 9Neoplasms, Plasma Cell 8Lymphoma, Non-Hodgkin 8Leukemia, Lymphocytic, Chronic, B-Cell 7Smoldering Multiple Myeloma 4Neuroblastoma 2Neoplasms 2Neoplasm, Residual 2Myelodysplastic Syndromes 2Leukemia, Plasma Cell 2Leukemia, Myelomonocytic, Chronic 2Hodgkin Disease 2Hematologic Diseases 2Burkitt Lymphoma 2Waldenstrom Macroglobulinemia 1Urinary Bladder Neoplasms 1Urethral Neoplasms 1Ureteral Neoplasms 1Precursor T-Cell Lymphoblastic Leukemia-Lymphoma 1Pancreatic Neoplasms 1Ovarian Neoplasms 1Malignant Plasma Cell Neoplasms 1Lymphoma, T-Cell, Peripheral 1Lymphoma, Large-Cell, Immunoblastic 1

Interventions

Cyclophosphamide 15venetoclax 11fludarabine 10Cytarabine 10Mycophenolic Acid 6Azacitidine 6fludarabine phosphate 5Daunorubicin 5Busulfan 5ruxolitinib 4ponatinib 4blinatumomab 4Whole-Body Irradiation 4Vincristine 4Tacrolimus 4Rituximab 4Methotrexate 4Dexamethasone 4asciminib 3Mercaptopurine 3Inotuzumab Ozogamicin 3Granulocyte Colony-Stimulating Factor 3Cyclosporine 3revumenib 2quizartinib 2pegaspargase 2nilotinib 2ibrutinib 2Thioguanine 2Prednisone 2

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Leukemia × Lenalidomide × 90 days × Clear all
NCT01446133 2026-05-22

Combination of Lenalidomide and Rituximab in Chronic Lymphocytic Leukemia/Small Lymphocytic Lymphoma (CLL-SLL)

M.D. Anderson Cancer Center

Phase 2 Active not recruiting
120 enrolled
LymphoidOther hematologic neoplasm

Leukemia, Lymphoma, Leukemia, Lymphocytic, Chronic, B-Cell

Data powered by HemOnc (CC BY 4.0) Colophon âš¡